Literature DB >> 28376988

Improving Nursing Home Compliance via Revised Antipsychotic Use Survey Tool.

Linda L Bach, Donald L Lazzaretto, Clipper F Young, Paul W Lofholm.   

Abstract

OBJECTIVE: To analyze the effect of using a pharmacist-initiated antipsychotic use survey tool on improving nursing home compliance for appropriate antipsychotic use in patients with dementia.
DESIGN: Prospective chart review study.
SETTING: Two nursing homes in Marin County, California. PARTICIPANTS: Nursing home residents diagnosed with dementia and receiving antipsychotic medication. INTERVENTION: Pharmacist performing survey tool screening for appropriate antipsychotic use based on Centers for Medicare & Medicaid Services guidelines and using information from the survey tool as part of the pharmacist recommendations to the prescriber. MAIN OUTCOME MEASURES: Number of pharmacist recommendations indicated by the survey tool for antipsychotic gradual dose reduction (GDR) or discontinuation that are accepted by prescribers. Number and percent of residents on antipsychotic medication per nursing home prior and throughout the study period.
RESULTS: Of the final 20 study population residents, 12 were survey-recommended for GDR or antipsychotic discontinuation. Within the 12 recommendations, four were accepted by prescribers from one of the two nursing homes. Decline in antipsychotic use was observed in the same nursing home throughout the seven months from 28 residents (21%) to 19 residents (14%). No significant difference in antipsychotic use before and after intervention was observed in the other nursing home. Overall feedback reported intervention helpful and requested continued pharmacist involvement.
CONCLUSION: Nursing home compliance improved and antipsychotic use declined during pharmacist intervention at one nursing home. Multiple factors may be involved in pharmacist recommendation acceptance.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28376988     DOI: 10.4140/TCP.n.2017.228

Source DB:  PubMed          Journal:  Consult Pharm        ISSN: 0888-5109


  6 in total

Review 1.  Clinical and Economic Outcomes of Interventions to Reduce Antipsychotic and Benzodiazepine Use Within Nursing Homes: A Systematic Review.

Authors:  Daniel J Hoyle; Ivan K Bindoff; Lisa M Clinnick; Gregory M Peterson; Juanita L Westbury
Journal:  Drugs Aging       Date:  2018-02       Impact factor: 3.923

2.  A Cluster Randomized Controlled Trial Testing the Impact of Function and Behavior Focused Care for Nursing Home Residents With Dementia.

Authors:  Elizabeth M Galik; Barbara Resnick; Sarah D Holmes; Erin Vigne; Karen Lynch; Jeanette Ellis; Shijun Zhu; Erik Barr
Journal:  J Am Med Dir Assoc       Date:  2021-01-15       Impact factor: 7.802

3.  A structured medication review tool to promote psychotropic medication optimisation for adults with intellectual disability: feasibility study.

Authors:  Rory Sheehan; André Strydom; Louise Marston; Nicola Morant; Federico Fiori; Paramala Santosh; Angela Hassiotis
Journal:  BMJ Open       Date:  2019-12-15       Impact factor: 2.692

4.  The Effect of the NorGeP-NH on Quality of Life and Drug Prescriptions in Norwegian Nursing Homes: A Randomized Controlled Trial.

Authors:  Enrico Callegari; Jurate Šaltytė Benth; Geir Selbæk; Cato Grønnerød; Sverre Bergh
Journal:  Pharmacy (Basel)       Date:  2022-02-16

5.  Systematic review and narrative synthesis of pharmacist provided medicines optimisation services in care homes for older people to inform the development of a generic training or accreditation process.

Authors:  David John Wright; Vivienne Maskrey; Annie Blyth; Nigel Norris; David P Alldred; Christine M Bond; James Desborough; Carmel M Hughes; Richard Charles Holland
Journal:  Int J Pharm Pract       Date:  2019-11-12

6.  Association of Focused Medication Review With Optimization of Psychotropic Drug Prescribing: A Systematic Review and Meta-analysis.

Authors:  Rory Sheehan; André Strydom; Emma Brown; Louise Marston; Angela Hassiotis
Journal:  JAMA Netw Open       Date:  2018-10-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.